SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2020
RESPIRERX PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
126 Valley Road, Suite C
Glen Rock, New Jersey
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code: (201) 444-4947
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|[ ]||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|[ ]||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|[ ]||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|[ ]||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 7.01. Regulation FD Disclosure.
Beginning on and after November 12, 2020, RespireRx Pharmaceuticals Inc. (the “Company”) will participate in meetings with third parties in which a corporate slide presentation will be presented. The presentation includes certain forward-looking information. A copy of the presentation materials is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Beginning on and after November 12, 2020, the Company will provide by email and may make available on its website or on social media, a short summary of the Company. The summary includes certain forward-looking information. A copy of the presentation materials is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 7.01 and the documents attached as Exhibit 99.1 and 99.2 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
|Exhibit Number||Exhibit Description|
|99.1||RespireRx Pharmaceuticals Inc. Corporate Presentation|
|99.2||RespireRx Pharmaceuticals Inc. Summary|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: November 12, 2020|
RESPIRERX PHARMACEUTICALS INC.
|By:||/s/ Jeff E. Margolis|
Jeff E. Margolis
SVP, CFO, Secretary and Treasurer
|RespireRx Pharmaceuticals Inc.||Company at a Glance|
The primary mission of RespireRx Pharmaceuticals is to develop innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling. We are developing treatment options that address conditions affecting millions of people, but for which there are few or poor treatment options, including obstructive sleep apnea (“OSA”), attention deficit hyperactivity disorder (“ADHD”), epilepsy, chronic pain and recovery from spinal cord injury (“SCI”). Based on our broad patent portfolios, RespireRx is developing a pipeline of new drug products within its two distinct business units:
(i) ResolutionRx is developing pharmaceutical cannabinoids, particularly dronabinol, a synthetic form of ∆9-tetrahydrocannabinol (“Δ9-THC”) for the treatment of OSA
(ii) EndeavourRx is developing neuromodulators, which include AMPAkines and GABAkines, proprietary compounds that positively modulate (positive allosteric modulators or “PAMs”) AMPA-type glutamate receptors and GABAA receptors, respectively.
Status of Lead Products Under Development
● Highly desirable assets with 3 clinical stage drugs and confirmed efficacy
● Expanding portfolio of novel preclinical compounds across multiple therapeutic categories and indications
● World Class Management Team and Board of Directors
● Broad flexibility in modeling mechanisms of investment
● Funding commitments secured through 2021
● Strategic Partners afforded the opportunity to share in the financial growth from early clinical to commercialization
● Exemplary regulatory and financial compliance history with government agencies
● Key clinical supply chains for dronabinol established
ResolutionRx – Two successful Phase 2 clinical trials have been completed demonstrating the ability of dronabinol to reduce the symptoms of OSA. The Company has designed and is developing proprietary, patent-pending dronabinol formulations that, if successful, could prove to be superior to existing formulations and not only extend market exclusivity for the treatment of OSA, but other indications as well.
CX717 and CX1739, our lead clinical AMPAkines, have successfully completed multiple Phase 1 safety trials with no drug-associated serious adverse events. Both compounds have also completed Phase 2 efficacy trials demonstrating target engagement, by antagonizing the process of opioid-induced respiratory depression (“OIRD”). CX717 has successfully completed a Phase 2 trial demonstrating the ability to significantly reduce the symptoms of adult ADHD.
KRM-II-81, our lead GABAkine, has demonstrated highly desirable properties in animal models of drug resistant epilepsy and chronic pain, with greatly reduced liability to produce side effects associated with current treatments. The anticonvulsant action of KRM-II-81 was confirmed by microelectrode recordings from slices obtained from freshly excised cortex from epileptic patients.
Executive Management Team
Tim Jones, CEO and President
Arnold Lippa, CSO
Jeff Margolis, CFO
126 Valley Rd.
Glen Rock, NJ 07452
For additional information, the reader is directed to SEC filings that can be found on the Company website - www.RespireRx.com